Ireland· IE-PA-EU/1/22/1704/002
Livmarli 19 mg/mL oral solution
A maralixibat chloride product containing maralixibat chloride, registered in Ireland by Mirum Pharmaceuticals International B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Maralixibat chloride is registered in 11 of 19 countries.
Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Maralixibat chloride · ATC A05AX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Maralixibat Chloride
- Manufacturer
- Mirum Pharmaceuticals International B.V.
- Country
- Ireland (IE)
- ATC code
- A05AX04
- ATC class
- Maralixibat chloride
- Defined daily dose
- 28.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1704/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Maralixibat chloride in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLivmarli 19 mg/mlMirum Pharmaceuticals International
- CzechiaLIVMARLIMirum Pharmaceuticals International B.V., Amsterdam
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- IcelandLivmarliMirum Pharmaceuticals International B.V.
- SwedenLivmarli 19 mg/ml Oral lösningMirum Pharmaceuticals International B.V.
- United StatesLivmarliMirum Pharmaceuticals Inc.
- SpainLIVMARLI 10 MG COMPRIMIDOSMirum Pharmaceuticals International B.V.
- United KingdomLivmarli 10mg tabletsMirum Pharmaceuticals International BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Livmarli
- Liechtenstein · Livmarli
- Norway · Livmarli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5d82694c-ddc3-4821-95d7-d55b2724aa46 GET /v1/drugs/5d82694c-ddc3-4821-95d7-d55b2724aa46?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral solution",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A05AX04"
],
"strength": null,
"pa_number": "EU/1/22/1704/002",
"substances": [
"Maralixibat Chloride"
],
"legal_basis": "Known active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/02/2026",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about maralixibat chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.